Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
| Autor: | Björn Hornestam, Lars H Lindholm, Kristian Wachtell, Eva Gerdts, Richard B. Devereux, Mika Lehto, Hans Ibsen, Sverre E. Kjeldsen, Stevo Julius, Björn Dahlöf, Michael H. Olsen, Markku S. Nieminen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Angiotensin receptor business.industry Atrial fibrillation 030204 cardiovascular system & hematology medicine.disease Left ventricular hypertrophy Atenolol Angiotensin II 3. Good health Surgery 03 medical and health sciences 0302 clinical medicine Losartan Blood pressure Internal medicine medicine Cardiology 030212 general & internal medicine Cardiology and Cardiovascular Medicine business Stroke circulatory and respiratory physiology medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 45:712-719 |
| ISSN: | 0735-1097 |
| Popis: | Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF). Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF. Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 ± 1.0 years. Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|